LXRX Share Price Performance
US$1.49
0.51 (52.79%)
45.8% undervalued intrinsic discount
US$2.75
Fair Value
Price US$1.49
AnalystConsensusTarget US$2.75
Fair ValueUS$2.75
Share Pricen/a
Lexicon Pharmaceuticals, Inc. Stock Price
- 1 Narratives written by author
- 2 Comments on narratives written by author
- 28 Fair Values set on narratives written by author
LXRX Community Narratives
AN
Fair Value US$2.75 45.8% undervalued intrinsic discount
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
0users have liked this narrative
2users have commented on this narrative
24users have followed this narrative
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Key Takeaways Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets. Strategic licensing and cost reduction initiatives aim to boost revenue streams while improving net margins and profitability.Read more
0users have liked this narrative
2users have commented on this narrative
24users have followed this narrative
AN
US$2.75
45.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-6.62% p.a.
Profit Margin
16.25%
Future PE
160.15x
Share price in 2028
US$3.35
Snowflake Analysis
Lexicon Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.19
- -6.98%
- -96.77%
- 47.0%
About LXRX
- Founded
- 1995
- Employees
- 103
- CEO
- WebsiteView website
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
